This report demonstrates the safe use of anti-amyloid therapies in Alzheimer's disease among individuals with HIV, suggesting a new treatment pathway.
INTRODUCTION Human immunodeficiency virus (HIV) therapies now support survival into advanced ages by suppressing HIV replication and preserving immune function. Alzheimer's disease (AD), the most common neurologic degenerative condition, may now be treated with anti‐amyloid therapies (AAT). HIV was an exclusionary criterion in clinical trials for AAT, leaving the safety and efficacy of these medications unknown in this setting. METHODS We report the development of AD supported by careful evaluations and biomarkers over a 10‐year period in a person living with well‐controlled HIV infection. RESULTS AD was diagnosed with consistent clinical and biomarker evidence. AAT was successfully administered without complications. HIV therapy remained effective. DISCUSSION This report provides early evidence that AAT can be safely administered without detrimental effects on HIV therapy. The rapidly enlarging elderly HIV population will include an increasing number of individuals with AD who may benefit from this knowledge.
No takes yet. Share an insight, caveat, or question.
Clifford et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: